Chongzhao Ran

This study demonstrates that molecularly produced light from ADLumin-5 can degrade misfolded proteins like beta-amyloid and reduce their toxicity in vitro and in vivo.

The paper discovers abundant nanoscale lymphatic-like vessels in brain parenchyma of mice and humans, suggesting a previously unrecognized system for metabolic waste clearance.

This paper introduces a chemiluminescence probe, ADLumin-1, that enables both generic and precise detection of misfolded proteins in neurodegenerative disease models.

This study develops and evaluates [18F]P4B-2412 as a PET radioligand for imaging PDE4B, showing high binding, specificity, and metabolic stability in rodent models.

The paper uses pupillary light response-driven fMRI in awake mice to identify brain-wide biomarkers of Alzheimer's disease by analyzing altered neuromodulatory patterns and functional connectivity.

This study identifies multi-copper oxidases (MCOs) as enzymes capable of degrading amyloid beta (Aβ) peptides, with ascorbate oxidase showing the strongest effect, and demonstrates their potential to mitigate Aβ-induced neuronal toxicity.

This study shows aerobic exercise improves microvascular perfusion and oxygenation in deep brain regions of aged mice, correlating with better cognitive function.

This paper develops a platform combining graphene-assisted Raman spectroscopy and machine learning to rapidly screen Alzheimer's disease biomarkers in mouse brains, achieving 98% classification accuracy.

This paper characterizes CRANAD-2 for detecting amyloid-beta deposits in Alzheimer's mouse models using multi-spectral optoacoustic tomography and fluorescence imaging.

This paper demonstrates the use of bioluminescence imaging with AkaLumine to report amyloid beta levels in Alzheimer's disease models and shows its potential for monitoring disease progression and therapy.